Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announces successful new study results from the long-term blinded placebo crossover group from the U.S ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Nymox Pharma (NYMX) Adds to Wednesday's Big GainsAugust 25, 2016 8:07 AM Nymox Pharma (NYMX) Ramps to Session Highs Following Fexapotide Phase 3 DataAugust 24, 2016 3:05 PM Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of SurgeryAugust 24, 2016 12:18 PM